For children 5 years and older with Duchenne muscular dystrophy, KYMBEE™—with the Upsher‑Smith Promise of Support® Program—delivers more than medicine. Accessing the right treatment matters. KYMBEE is the only deflazacort backed by Upsher‑Smith’s comprehensive Promise of Support® Program, which is designed to help children with Duchenne receive the treatment they need as easily, quickly, and reliably as possible. For children 5 years and older with Duchenne muscular dystrophy, KYMBEE™—with the Upsher‑Smith Promise of Support® Program—delivers more than medicine. Accessing the right treatment matters. KYMBEE is the only deflazacort backed by Upsher‑Smith’s comprehensive Promise of Support® Program, which is designed to help children with Duchenne receive the treatment they need as easily, quickly, and reliably as possible. Caring for a child with Duchenne muscular dystrophy can be demanding—physically, emotionally, and logistically. Between appointments, possible insurance challenges, and daily routines, caregivers and families can shoulder a heavy load. While no program can take away every difficulty on your journey, the Upsher‑Smith Promise of Support® Program is designed to help relieve some of the stress associated with accessing medication to treat Duchenne. Promise of Support® Program at a glance We’ll work with your insurance to help navigate prior authorizations and appeals so you don’t have to. Expert help with benefits investigation and coverage navigation Prior authorization and appeal support $0 copay* for eligible commercially insured patients Bridge Supply available for therapy continuity and Quick Start available as needed 24/7 access to a pharmacist for personalized help Free home delivery and medication refill reminders Our Promise of Support® Program *Limitations apply. KYMBEE (deflazacort) Tablets is a corticosteroid indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 5 years of age and older. SELECTED IMPORTANT SAFETY INFORMATION: Contraindications: KYMBEE is contraindicated in patients with a hypersensitivity to deflazacort or any of the inactive ingredients. Manufactured in the USA.† Upsher‑Smith, a trusted U.S.-based pharmaceutical company, delivers consistent supply and industry-leading support. †Sourced using components from Italy. Getting access shouldn’t be the hardest part of care. For too long, access to deflazacort may have presented challenges when caring for children with Duchenne. That’s why Upsher‑Smith created the Promise of Support® Program—backed directly by us and delivered by our trusted specialty pharmacy partner—to help make access to treatment easier and more reliable. The program connects caregivers with a specialized Care Team who can help manage the steps—from insurance navigation and affordability options to delivery and day-to-day questions. Our goal is to simplify the process, so your energy can stay where it belongs—with the child you love. Getting started with KYMBEE Care matters We’re proud to stand with those affected by rare diseases, helping provide consistent access to treatment and compassionate support every step of the journey. Deflazacort, the medicine in KYMBEE, was the first U.S. Food and Drug Administration (FDA) approved corticosteroid for DMD. Since approval of deflazacort, the healthcare community has gained nearly a decade of experience with the medicine to help maintain muscle strength in patients with Duchenne muscular dystrophy (DMD).1,2* If you’re considering a change in your child’s treatment, talk with their healthcare provider to see whether KYMBEE may be right for them. Upsher‑Smith’s best-in-class Promise of Support® Program offers resources intended to help families navigate insurance, save on medication copays,† and coordinate elements of the medication care plan. * The innovator deflazacort approved by the FDA in 2017 was EMFLAZA®. KYMBEE (deflazacort) tablets are a generic AB-rated, therapeutically equivalent version of EMFLAZA (deflazacort) tablets for the treatment of DMD in patients 5 years of age or older. FDA-approved generic medicines work in the same way and are expected to have the same clinical benefit and risks as their brand-name counterparts. A generic medicine is required to be the same as a brand-name medicine in dosage, safety, effectiveness, strength, stability, and quality, as well as in the way it is taken. † Limitations apply. References: 1. KYMBEE (deflazacort) tablets [Prescribing Information]. Maple Grove, MN: Upsher-Smith Laboratories, LLC. 2. Orange book: approved drug products with therapeutic equivalence evaluations. US Food and Drug Administration. Updated October 2025. Accessed February 15, 2026. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm IMPORTANT SAFETY INFORMATION & INDICATION for KYMBEE™ (deflazacort) Tablets Who should not take KYMBEE? Do not take if you have had hypersensitivity, including allergic reactions, to deflazacort (the active ingredient in KYMBEE) or to any of the inactive ingredients in KYMBEE. What is the most important information I should know about KYMBEE? KYMBEE can cause changes in endocrine (hormone) function. Do not stop taking KYMBEE, or change the amount being taken, without first checking with a healthcare provider, as there may be a need for gradual dose reduction to decrease the risk of adrenal insufficiency and steroid “withdrawal syndrome.” Acute adrenal insufficiency can occur if corticosteroids, including KYMBEE, are withdrawn abruptly, and can be life threatening. A steroid “withdrawal syndrome” may also occur following abrupt discontinuance of corticosteroids. For patients already taking corticosteroids during times of stress, the amount of KYMBEE prescribed may need to be increased. There is an increased risk of infection when taking KYMBEE. Tell a healthcare provider if the patient has had recent or ongoing infections or if they have recently received a vaccine. Seek medical advice immediately if the patient develops fever or other signs of infection. Some infections can potentially be severe and life threatening. Patients should avoid exposure to chickenpox or measles and alert their healthcare provider immediately if they are exposed. KYMBEE can cause an increase in blood pressure and water retention. If this occurs, dietary salt restriction and potassium therapy may be needed. There is an increased risk of developing a hole in the stomach or intestines in patients with certain gastrointestinal disorders when taking corticosteroids like KYMBEE. KYMBEE can cause behavior and mood changes that can be severe. Seek medical attention if any behavioral or mood changes develop. There is a risk of osteoporosis with prolonged use of KYMBEE, which can lead to fractures in the spine and in long bones. KYMBEE may cause cataracts or glaucoma. A healthcare provider should monitor for these conditions if therapy is continued for more than 6 weeks. Immunizations should be up-to-date according to immunization guidelines prior to starting therapy with KYMBEE. Live attenuated or live vaccines should be administered at least 4 to 6 weeks prior to starting KYMBEE. Live attenuated or live vaccines should not be used in patients taking KYMBEE. KYMBEE can cause serious skin rashes. Seek medical attention at the first sign of a rash. Rare instances of anaphylaxis, a severe allergic reaction, have occurred in patients receiving corticosteroid therapy, including KYMBEE. Before taking KYMBEE, tell a healthcare provider about all medical conditions, including if the patient: is pregnant or planning to become pregnant. KYMBEE can harm an unborn baby. is breastfeeding or planning to breastfeed. KYMBEE may appear in breastmilk and could affect a nursing child. Certain medications can cause an interaction with KYMBEE. Tell a healthcare provider about all the medicines you are taking, including over-the-counter medicines (such as insulin, aspirin or other non-steroidal anti-inflammatory drugs), dietary supplements, and herbal products. Alternate treatment, dosage adjustment, and/or special test(s) may be needed during the treatment. What are the side effects of KYMBEE? The most common side effects include: facial puffiness or Cushingoid appearance, weight increased, increased appetite, upper respiratory tract infection, cough, frequent daytime urination, unwanted hair growth, abdominal obesity, and colds. These are not all of the possible side effects. Call a healthcare provider for medical advice about side effects. This safety information is not comprehensive. Please see the full Prescribing Information for more information on KYMBEE. You can also visit www.upsher-smith.com or call 1-888-650-3789. You are encouraged to report suspected adverse reactions to the FDA by visiting www.fda.gov/medwatch or by calling 1-800-FDA-1088. What is KYMBEE? KYMBEE (deflazacort) Tablets are a prescription medicine used to treat Duchenne muscular dystrophy (DMD) in patients 5 years of age and older.